Health Care & Life Sciences » Pharmaceuticals | Affimed Therapeutics

Affimed Therapeutics B.V. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
5,719.90
48,069.20
83,362.70
47,351.90
47,836.30
124,378.10
Total Accounts Receivable
1,379.30
1,136.20
994.00
2,378.50
1,323.30
1,633.60
Inventories
192.90
240.80
247.70
207.80
289.40
297.20
Other Current Assets
-
-
491.00
544.30
960.60
442.40
Total Current Assets
7,292.10
49,446.30
85,095.30
50,482.40
50,409.60
126,751.30
Net Property, Plant & Equipment
1,424.80
1,178.60
994.00
867.00
1,336.50
1,616.40
Intangible Assets
217.70
87.10
78.20
58.00
78.10
64
Total Assets
8,956.70
50,712.00
86,167.50
51,407.50
51,824.10
132,804.30
ST Debt & Current Portion LT Debt
6,614.20
-
1,599.00
1,026.30
3,702.10
Accounts Payable
5,321.60
4,548.60
4,066.00
4,752.70
4,058.70
Other Current Liabilities
8,650.80
2,976.70
4,050.80
940.80
1,236.80
Total Current Liabilities
20,586.60
7,525.30
9,715.90
6,719.80
8,997.60
Long-Term Debt
107,404.30
4,713.10
3,371.90
3,815.00
4,906.50
Deferred Taxes
22.00
-
-
-
-
Other Liabilities
17,690.10
-
-
-
-
Total Liabilities
145,681.00
12,238.40
13,087.70
10,534.80
13,904.10
Common Equity (Total)
136,724.30
38,473.50
73,079.70
40,872.60
37,920.10
Total Shareholders' Equity
136,724.30
38,473.50
73,079.70
40,872.60
37,920.10
Total Equity
136,724.30
38,473.50
73,079.70
40,872.60
37,920.10
Liabilities & Shareholders' Equity
8,956.70
50,712.00
86,167.50
51,407.50
51,824.10

About Affimed Therapeutics

View Profile
Address
Technologiepark
Heidelberg Baden Wuerttemberg 69120
Germany
Employees -
Website http://www.affimed.com
Updated 07/08/2019
Affimed NV is a clinical stage biopharmaceutical company, which engages in discovering and developing highly targeted cancer immunotherapies. The company has three proprietary platform technologies which includes: NK-cell TandAbs, T-cell TandAbs and Trispecific Abs. The company was founded in 2000 and is headquartered in Heidelberg, Germany.